IECURE, INC.
🇺🇸United States
Long-term Follow-up (LTFU) Study of Participants in Any iECURE Protocol Using an Investigational Product (IP)
Recruiting
- Conditions
- Ornithine Transcarbamylase DeficiencyOrnithine Transcarbamylase Deficiency DiseaseUrea Cycle Disorders, Inborn
- First Posted Date
- 2025-02-03
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- iECURE, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT06805695
- Locations
- 🇬🇧
Great Ormond Street Hospital, London, United Kingdom
An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency (OTC-HOPE)
Phase 1
Recruiting
- Conditions
- Ornithine Carbamoyltransferase Deficiency (Disorder)Ornithine Transcarbamylase DeficiencyOrnithine Transcarbamylase Deficiency DiseaseUrea Cycle Disorders, Inborn
- Interventions
- Genetic: ECUR-506
- First Posted Date
- 2024-02-13
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- iECURE, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT06255782
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸UCLA Mattel Children's Hospital, Los Angeles, California, United States
🇺🇸Children's Hospital of Colorado, Anshutz Medical Campus, Aurora, Colorado, United States
© Copyright 2025. All Rights Reserved by MedPath